Biopharmaceutical manufacturer Gilead Sciences has committed to R&D and manufacturing investments in the U.S. that the company said will create $43 billion in value to the U.S. economy over the next five years through direct capital investment and job creation. This investment further bolsters Gilead’s domestic research, development, and manufacturing capabilities while advancing the company’s mission to discover and develop medicines.
Details of the overall investment include a newly announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spend of $21 billion in U.S. manufacturing and R&D through 2030. Together, this is estimated to generate an additional $11 billion in U.S. economic impact.
This next phase of investment will support the building three new facilities, upgrading three existing sites to expand U.S. manufacturing and R&D capabilities, and investing in new technology and advanced engineering initiatives. Moreover, the additional $11 billion will cover:
- $4 billion allocated to capital projects, including labs and equipment.
- $5 billion dedicated to technology, operations, and R&D site activities.
- $2 billion invested in digital and advanced engineering initiatives
- Creation of approximately 800 new direct jobs and support more than 2,200 indirect jobs by 2028.
These current investments further build on Gilead’s history of U.S. investment with $15 billion over the last 10 years.